The Daily Pennsylvanian covered Penn Medicine’s new Center for Personalized Diagnostics, a joint venture between the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center. The center integrates Molecular Genetics, Pathology Informatics and Genomic Pathology, and uses cutting-edge, genome-wide tests to see the rare mutations within tumors to help guide clinicians to more targeted and effective treatments. “So far we’ve looked at about 30 patients with acute leukemia and 95 percent of them have had genetic abnormalities identified that were not done by traditional tests,” said Selina Luger, MD, director of the Leukemia Program in the Abramson Cancer Center. The goal, she said, is to develop novel therapies that are less toxic and allow for treatment without the side effects that result from chemotherapy. “It is thrilling for us to be able to offer new hope to patients. Our entire team is very gratified by our early experience,” said David Roth, MD, PhD, chairman of the Department of Pathology and Laboratory Medicine. Robert Daber, PhD, the Technical Director of Clinical Genomics at the Center for Personalized Diagnostics, is also quoted in the article.
Read the entire Daily Pennsylvanian article